Meeting
2023 ASCO Annual Meeting
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Authors
Xinfeng Chen
Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Xinfeng Chen , Ping Yu , Ling Li , Lei Zhang , Xudong Zhang , Jianmin Huang , Jia Liu , Gui Li , Jiaping He , Hua Zhang , Wei Zhao , Lihong Weng , Wenjie Yin , Lianjun Shen , Wei Cao , Wenling Li , Mingzhi Zhang , Yi Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
ChiCTR2100047061
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7562)
DOI
10.1200/JCO.2023.41.16_suppl.7562
Abstract #
7562
Poster Bd #
113
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2019 ASCO Annual Meeting
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
First Author: Lu Han
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang